Last10K.com

Nuo Therapeutics, Inc. (AURX) SEC Filing 10-Q Quarterly report for the period ending Friday, March 31, 2017

Nuo Therapeutics, Inc.

CIK: 1091596 Ticker: AURX
Document And Entity Information - shares
3 Months Ended
Mar. 31, 2017
May 05, 2017
Document Information [Line Items]  
Entity Registrant NameNuo Therapeutics, Inc. 
Entity Central Index Key0001091596 
Trading Symbolnuot 
Current Fiscal Year End Date--12-31 
Entity Filer CategorySmaller Reporting Company 
Entity Current Reporting StatusYes 
Entity Voluntary FilersNo 
Entity Well-known Seasoned IssuerNo 
Entity Common Stock, Shares Outstanding (in shares) 9,927,112
Document Type10-Q 
Document Period End DateMar. 31, 2017 
Document Fiscal Year Focus2017 
Document Fiscal Period FocusQ1 
Amendment Flagfalse 

View differences made from one quarter to another to evaluate Nuo Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Nuo Therapeutics, Inc..

Continue

Assess how Nuo Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Nuo Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets (unaudited)
Condensed Consolidated Balance Sheets (unaudited) (parentheticals)
Condensed Consolidated Statements Of Cash Flows (unaudited)
Condensed Consolidated Statements Of Operations (unaudited)
Note 1 - Description Of Business And Bankruptcy Proceedings
Note 1 - Description Of Business And Bankruptcy Proceedings (details Textual)
Note 10 - Commitments And Contingencies
Note 10 - Commitments And Contingencies (details Textual)
Note 2 - Fresh Start Accounting
Note 2 - Fresh Start Accounting (details Textual)
Note 2 - Fresh Start Accounting (tables)
Note 2 - Fresh Start Accounting - Cumulative Impact Of Fresh Start Adjustments On Apic (details)
Note 2 - Fresh Start Accounting - Cumulative Impact Of The Reorganization Adjustments (details)
Note 2 - Fresh Start Accounting - Fresh Start Adjustments (details)
Note 2 - Fresh Start Accounting - Reorganization Value (details)
Note 2 - Fresh Start Accounting - Reorganization Value Of Fresh Start Adjustments (details)
Note 2 - Fresh Start Accounting - Summary Of Reorganization Items, Net (details)
Note 3 - Liquidity And Summary Of Significant Accounting Policies
Note 3 - Liquidity And Summary Of Significant Accounting Policies (details Textual)
Note 3 - Liquidity And Summary Of Significant Accounting Policies (tables)
Note 3 - Liquidity And Summary Of Significant Accounting Policies - Anti-dilutive Securities Excluded From The Computation Of Diluted Earnings (loss) Per Share (details)
Note 3 - Liquidity And Summary Of Significant Accounting Policies - Summary Stock Option Valuation Assumptions (details)
Note 3 - Liquidity And Summary Of Significant Accounting Principles - Summary Of Concentration Risk (details)
Note 4 - Distribution, Licensing And Collaboration Arrangements
Note 4 - Distribution, Licensing And Collaboration Arrangements (details Textual)
Note 5 - Property And Equipment
Note 5 - Property And Equipment (details Textual)
Note 5 - Property And Equipment (tables)
Note 5 - Property And Equipment - Property And Equipment, Net (details)
Note 6 - Goodwill And Other Intangible Assets
Note 6 - Goodwill And Other Intangible Assets (details Textual)
Note 6 - Goodwill And Other Intangible Assets (tables)
Note 6 - Goodwill And Other Intangible Assets - Annual Amortization Expense (details)
Note 6 - Goodwill And Other Intangible Assets - Changes In Goodwill (details)
Note 6 - Goodwill And Other Intangible Assets - Intangible Assets (details)
Note 7 - Debt
Note 7 - Debt (details Textual)
Note 8 - Equity And Share-based Compensation - Stock Options, Activity (details)
Note 8 - Equity And Stock-based Compensation
Note 8 - Equity And Stock-based Compensation (details Textual)
Note 8 - Equity And Stock-based Compensation (tables)
Note 8 - Equity And Stock-based Compensation - Stock-based Compensation Expense (details)
Note 9 - Fair Value Measurements
Note 9 - Fair Value Measurements (details Textual)
Significant Accounting Policies (policies)

Material Contracts, Statements, Certifications & more

Nuo Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: AURX
CIK: 1091596
Form Type: 10-Q Quarterly Report
Accession Number: 0001437749-17-009226
Submitted to the SEC: Mon May 15 2017 4:11:57 PM EST
Accepted by the SEC: Mon May 15 2017
Period: Friday, March 31, 2017
Industry: Surgical And Medical Instruments And Apparatus

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/aurx/0001437749-17-009226.htm